Dual benefit of supplementary oral 5 ‐aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model

ConclusionsOur study provides novel and comprehensive insights into the dual benefits including radiosensitizing PCa tumor tissues and radioprotection of normal pelvic organs from radiation therapy. Knowledge of the underlying mechanism will facilitate the search for optimal treatment parameters for supplemental oral ALA during radiotherapy for PCa.

Source: The Prostate - November 18, 2018 Category: Urology & Nephrology Authors: Makito Miyake, Nobumichi Tanaka, Shunta Hori, Sayuri Ohnishi, Hiroo Takahashi, Tomomi Fujii, Takuya Owari, Kenta Ohnishi, Kota Iida, Yosuke Morizawa, Daisuke Gotoh, Yoshitaka Itami, Yasushi Nakai, Takeshi Inoue, Satoshi Anai, Kazumasa Torim Tags: ORIGINAL ARTICLE Source Type: research